Nachrichten und Videos - HELIUS MEDICAL TECHNOLOGIES

-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke -- -- Shepherd Center, a top neurorehabilitation hospital, is the third site in Helius’ U.S. registrational program for Portable Neuromodulation Stimulator (PoNS®) in stroke -- -- The single-arm study will evaluate PoNS in treating gait and balance deficits in chronic stroke survivors -- -- Regulatory submission seeking marketing authorization for stroke...

-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) -- -- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell...

-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023. Fourth Quarter and Recent Business Updates Secured Healthcare Common Procedure Coding System (“HCPCS”) Level II codes for...

NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief...

-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month -- -- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in chronic stroke survivors -- -- Results will support efforts to achieve U.S. authorization under PoNS’s breakthrough designation for stroke -- NEWTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...

NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the 36th Annual ROTH Conference, March 17-19, 2024, Laguna Nigel, CA, as follows: Date: Monday, March 18, 2024...

-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances through the Company’s At-The-Market (“ATM”) program extends cash runway into the third quarter 2024 -- NEWTOWN, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel...

-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on clinical program feasibility streamlines cost and timeline and leverages trials with the Medical University of South Carolina and Brooks Rehabilitation -- -- Studies and real-world evidence results will be submitted for regulatory authorization under PoNS’s breakthrough designation for stroke -- --...

NEWTOWN, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) is expanding its presence at the 2024 American Physical Therapy Association (APTA) Combined Sections Meeting (CSM), held February 15 through February 17 at the Boston Convention and Exposition Center: In addition to exhibiting its innovative Portable Neuromodulation Stimulator (PoNS®) at booth 7074, the company also is hosting an after-hours event on February 16. At both venues, Helius will...

-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Results of the study will support efforts to achieve U.S. authorization under PoNS’s breakthrough designation for stroke -- NEWTOWN, Pa., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Helius Medical...

NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, will present at the NobleCon 19th Annual Emerging Growth Equity Conference as follows: Date: Tuesday, December 5, 2023 Time: 2:00pm ET Location: Boca Raton, Florida Investors...

-- Cash runway extended into Q2 2024 -- -- Company to host call at 4:30pm today -- NEWTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023. Third Quarter and Recent Business Updates Q3 2023 revenue of $143 thousand, compared to $196...

-- Collaborative project between Pacific Blue Cross and HealthTech Connex designed to reduce long-term disability and improve quality of life for individuals suffering from traumatic brain injury (“TBI”) -- -- 56% of study participants who were previously unable to work due to TBI returned to their prior occupations after 14 weeks of PoNS Therapy -- NEWTOWN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech...

-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- -- Expects to report approximately $7.0 million in cash, cash equivalents and proceeds receivable from warrant exercises, extending cash runway into Q2 2024 -- -- Expects to report cash used in operating activities for the first nine months of 2023 ranging from $8.3 - $8.4 million, and for Q3 $2.4 -...

-- PoNS ® devices to be provided to a least five sites in five separate administrative regions within Québec -- -- Government-funded initiative will evaluate the benefits of PoNS Therapy™ when used by patients who have suffered the effects of stroke -- NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait...

NEWTOWN, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Jeff Mathiesen, Chief Financial Officer, will participate at two upcoming conferences as follows: JonesTrading 2023 Healthcare Summit (1-on-1s Only) Date: Tuesday, October 10, 2023 Location: Miami, Florida Investors and...

-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology -- -- PoNS system and mouthpiece will be included in pharmacy database utilized by 17 out 20 of the top-grossing pharmacy benefit managers (PBMs) –-- -- PoNS expected to be one of few products with both pharmacy and device codes, providing dual paths for potential reimbursement -- NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the...

Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month NEWTOWN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will exhibit at the Academy of Neurologic Physical Therapy 2023...

NEWTOWN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has signed an agreement with the School of Rehabilitation at the Université de Montréal (“UdeM”) for the purchase of ten PoNS devices to be used in a research project linked to stroke recovery. “We are excited to work...

-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS ® ) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, clinical data, safety profile -- -- Forum brings together world experts from the core disciplines of clinical neurosciences and rehabilitation -- NEWTOWN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech...